Targeted therapy and their ocular complications

Denis Jusufbegovic, L. Pierre, Arun D. Singh

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


The rapid advancements in the field of oncology have resulted in the transition from cytotoxic chemotherapeutic agents to molecularly targeted therapies that interfere with cellular signaling pathways important for the survival and propagation of neoplastic cells. Some of these agents have changed the landscape in the management of several hematologic and solid malignancies. Molecularly targeted agents are selected and designed to provide the maximal antitumor affect with the minimal functional alteration of the normal healthy cells. However, the complexity of cellular pathways proves very difficult to design therapeutic agents that do not overlap with the physiologic activities of the normal human tissues. The recognition of a myriad of distinct adverse effects related to the molecularly targeted therapies has emerged over the last decade with their increased clinical usage.

Original languageEnglish (US)
Title of host publicationClinical Ophthalmic Oncology
Subtitle of host publicationBasic Principles and Diagnostic Techniques, Second Edition
PublisherSpringer Berlin Heidelberg
Number of pages10
ISBN (Electronic)9783642404894
ISBN (Print)9783642404887
StatePublished - Jan 1 2014
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Targeted therapy and their ocular complications'. Together they form a unique fingerprint.

  • Cite this

    Jusufbegovic, D., Pierre, L., & Singh, A. D. (2014). Targeted therapy and their ocular complications. In Clinical Ophthalmic Oncology: Basic Principles and Diagnostic Techniques, Second Edition (pp. 123-132). Springer Berlin Heidelberg.